By Fineline Cube 
Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed a new round of funding, raising several hundred million yuan. The investment was led by a major domestic venture capital firm and saw participation from renowned institutional investors, including Heda Capital and BlueRun Ventures.
Funding Allocation
The newly secured capital will be primarily allocated to expanding the company’s marketing team, enhancing its global market reach, and accelerating the development of next-generation products. This strategic allocation aims to solidify Moyang Bio’s position and industrialization in the regenerative aesthetics sector.
Company Background
Founded in 2018, Moyang Bio is the creator of aphranel, a premium injectable calcium hydroxylapatite (CaHA) microsphere facial filler. It holds the distinction of being the first domestically developed product of its kind to receive NMPA Class III medical device registration for aesthetic applications in China.
Future Plans
With this new funding, Moyang Bio plans to fast-track the global commercial rollout of its core products, including the aphranel magic CC needle. The company is positioned to increase its market penetration in the regenerative aesthetics field and more efficiently advance its next-generation product pipeline. This will further strengthen its global leadership in the precise control technology of CaHA materials.-Fineline Info & Tech